相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Glucose regulation of glucagon secretion
Erik Gylfe et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Steven E. Kahn et al.
LANCET (2014)
Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats
Takumi Nagata et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
Improved glycemic control in mice lacking Sglt1 and Sglt2
David R. Powell et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
被撤回的出版物: Betatrophin: A Hormone that Controls Pancreatic β Cell Proliferation (Retracted article. See vol. 168, pg. 326, 2017)
Peng Yi et al.
CELL (2013)
Role of KATP Channels in Glucose-Regulated Glucagon Secretion and Impaired Counterregulation in Type 2 Diabetes
Quan Zhang et al.
CELL METABOLISM (2013)
Tolbutamide Controls Glucagon Release From Mouse Islets Differently Than Glucose Involvement of KATP Channels From Both α-Cells and δ-Cells
Rui Cheng-Xue et al.
DIABETES (2013)
Adaptive changes of human islets to an obesogenic environment in the mouse
S. Gargani et al.
DIABETOLOGIA (2013)
The SLC2 (GLUT) family of membrane transporters
Mike Mueckler et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
Effects of a New SGLT2 Inhibitor, Luseogliflozin, on Diabetic Nephropathy in T2DN Rats
Naoki Kojima et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
In Vitro-In Vivo Correlation of the Inhibition Potency of Sodium-Glucose Cotransporter Inhibitors in Rat: A Pharmacokinetic and Pharmacodynamic Modeling Approach
Koji Yamaguchi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Glucose Transport by Acinar Cells in Rat Parotid Glands
Cedric Jurysta et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2012)
Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus
G. Luippold et al.
DIABETES OBESITY & METABOLISM (2012)
Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin-Nicotinamide-Induced Mildly Diabetic Mice
Atsuo Tahara et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2012)
Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats
James J. Devenny et al.
OBESITY (2012)
Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
Yin Liang et al.
PLOS ONE (2012)
Glucagon regulates its own synthesis by autocrine signaling
Barbara Leibiger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice
Masayuki Suzuki et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Early Growth Retardation and Insulin Resistance in JAZF1 KO Mice
Hui-Young Lee et al.
DIABETES (2011)
Transcriptomes of the major human pancreatic cell types
C. Dorrell et al.
DIABETOLOGIA (2011)
SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
Michael J. Jurczak et al.
DIABETES (2011)
Efficient gene delivery and silencing of mouse and human pancreatic islets
Bruno Lefebvre et al.
BMC BIOTECHNOLOGY (2010)
In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
M. Obermeier et al.
DRUG METABOLISM AND DISPOSITION (2010)
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Sunil Nair et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Upgrading Pretransplant Human Islet Culture Technology Requires Human Serum Combined With Media Renewal
Julie Kerr-Conte et al.
TRANSPLANTATION (2010)
CXCL10 Impairs β Cell Function and Viability in Diabetes through TLR4 Signaling
Fabienne T. Schulthess et al.
CELL METABOLISM (2009)
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
Songping Han et al.
DIABETES (2008)
Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes
S. A. Jabbour et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
Yoshikazu Fujimori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Evidence Based Selection of Housekeeping Genes
Hendrik J. M. de Jonge et al.
PLOS ONE (2007)
Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells
A. Abderrahmani et al.
DIABETOLOGIA (2007)
A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria
D Magen et al.
KIDNEY INTERNATIONAL (2005)
A common polymorphism in the upstream promoter region of the hepatocyte nuclear factor-4α gene on chromosome 20q is associated with type 2 diabetes and appears to contribute to the evidence for linkage in an Ashkenazi Jewish population
LD Love-Gregory et al.
DIABETES (2004)
Common variants of the hepatocyte nuclear factor-4α P2 promoter are associated with type 2 diabetes in the UK population
MN Weedon et al.
DIABETES (2004)
Regulation of hepatic fasting response by PPARγ coactivator-1α (PGC-1):: Requirement for hepatocyte nuclear factor 4α in gluconeogenesis
J Rhee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Identification and purification of functional human β-cells by a new specific zinc-fluorescent probe
B Lukowiak et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2001)
分享论文
